Clinical trials: Liver Tumour
Carcinoma, Hepatocellular, Biliary Tract Cancer
A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases
Phase I study of RO7119929 given orally to participants with unresectable advanced or metastatic primary liver cancers and other solid tumors with predominant liver involvement.
- Conditions
- Carcinoma, Hepatocellular, Biliary Tract Cancer, Secondary Liver Cancer, Liver Metastases
- Trial name
- NCT04338685
- Testing
- RO7119929, Tocilizumab
- Where
- 10 sites in United States, Denmark and 4 more
- Volunteers
- 55 people
- Sponsor
- Hoffmann-La Roche
Advanced or Metastatic Hepatocellular Cancer, Advanced or Metastatic Ovarian Cancer
A Study With Tasquinimod Treating Patients With Hepatocellular, Ovarian, Renal Cell and Gastric Cancers
This was an exploratory proof of concept study to determine the clinical activity of tasquinimod in patients with advanced or metastatic hepatocellular carcinoma, ovarian carcinoma, renal cell carcinoma and gastric carcinoma who…
- Conditions
- Advanced or Metastatic Hepatocellular Cancer, Advanced or Metastatic Ovarian Cancer, Metastatic Renal Cell Cancer, Advanced or Metastatic Gastric Carcinoma
- Trial name
- NCT01743469
- Testing
- Tasquinimod
- Where
- 24 sites in Belgium, Canada and 3 more
- Volunteers
- 201 people
- Sponsor
- Ipsen
Hepatocellular Carcinoma (HCC)
Computer Guided Microwave Liver Ablation
The goal of this clinical trial is to learn if the intraoperative use of a computer guidance software can improve the success of liver tumor ablation in adults.
- Trial name
- MWA Sim (NCT07226869)
- Testing
- Computer-Assisted Microwave Liver Ablation
- Where
- 2 sites in United States
- Volunteers
- 84 people
- Sponsor
- NE Scientific INC
Hepatocellular Carcinoma
Multiple Antigen Specific Cell Therapy (MASCT) for Hepatocellular Carcinoma(HCC) Patients After Radical Resection or Radio Frequency Ablation(RFA).
To prove that the efficacy and safety of 'MASCT group' is superior to 'non-treatment group' in patient undergone curative resection (RFA or operation) for hepatocellular carcinoma in China.
- Trial name
- HCC DC CTL (NCT02026362)
- Testing
- MASCT:Multiple Antigens Specific Cellular Therapy, The foundation treatment including against hepatitis b virus treatment using nucleoside analogue drug and protect liver treatment
- Where
- China
- Volunteers
- 100 people
- Sponsor
- HRYZ Biotech Co.
Carcinoma, Carcinoma, Hepatocellular
SIR-Spheres Study to Calculate the Radiation-Absorbed Dose of 99mTc-MAA
The goal of this interventional clinical trial is to evaluate the dose of radiation of Technetium-99m macroaggregated-albumin (99mTc-MAA) after an intra-arterial injection to the whole body and non-liver critical organs in…
- Conditions
- Carcinoma, Carcinoma, Hepatocellular, Liver Neoplasm
- Trial name
- MAApping (NCT05848947)
- Testing
- 99mTc-Macro Albumin Aggregate
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Sirtex Medical
Hepatocellular Carcinoma (HCC)
NWRD06 DNA Plasmid for HCC After Curative Resection.
This is a single-arm, open-label, multi-center Phase 2 clinical study to evaluate the efficacy and safety of Glypican3 (GPC3)-targeted DNA plasmid vaccine (NWRD06) in patients with GPC3-positive primary hepatocellular carcinoma…
- Trial name
- NCT07324304
- Testing
- NWRD06 administered by electroporation
- Where
- 6 sites in China
- Volunteers
- 30 people
- Sponsor
- Newish Technology (Beijing) Co., Ltd.
HCC, Liver Cancer
A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC
This study to evaluate the preliminary efficacy, safety and pharmacokinetics of PM8002 combined with PM1009 in Patients with first-line Hepatocellular Carcinoma.
- Trial name
- NCT06584071
- Testing
- PM8002, PM1009, atezolizumab
- Volunteers
- 140 people
- Sponsor
- Biotheus Inc.
Hepatocellular Carcinoma
Randomized Phase 1/2 Open-Label Trial of PR104 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
The current understanding of PR104 justifies the evaluation of PR104 with sorafenib in patients with hepatocellular carcinoma. These include: Hypoxia.
- Trial name
- NCT00862082
- Testing
- PR104 550 mg/m^2 + sorafenib, PR104 770 mg/m^2 + sorafenib
- Where
- 17 sites in United States, Hong Kong and 2 more
- Volunteers
- 14 people
- Sponsor
- Proacta, Incorporated
Hepatocellular Carcinoma
DEB-TACE for Hepatocellular Carcinoma
Patients enrolled in this study have been diagnosed with hepatocellular carcinoma (HCC) and are scheduled to have a procedure called drug-eluting bead trans-arterial chemoembolization (DEB-TACE).
- Trial name
- QED (NCT02748161)
- Testing
- DEB-TACE
- Where
- 11 sites in United States
- Volunteers
- 170 people
- Sponsor
- Surefire Medical, Inc.
Liver Cancer, Pancreatic Adenocarcinoma
Immunotherapy of Tumor With Autologous Tumor Derived Heat Shock Protein gp96
To evaluate the safety and effectiveness of autologous gp96 treatment of liver cancer and Pancreatic Adenocarcinoma
- Trial name
- NCT02133079
- Testing
- autologous gp96 vaccination
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Cure&Sure Biotech Co., LTD
Breast Neoplasms, Prostate Neoplasms
PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
A Phase 1 dose escalation and expansion study evaluating safety, tolerability and pharmacokinetics of PF-06952229 in adult patients with advanced solid tumors.
- Conditions
- Breast Neoplasms, Prostate Neoplasms, Neoplasms, Squamous Cell, Melanoma
- Trial name
- NCT03685591
- Testing
- PF-06952229, Enzalutamide
- Where
- 15 sites in United States
- Volunteers
- 49 people
- Sponsor
- Pfizer
Hepatocellular Carcinoma (HCC)
A Post Approval Study to Evaluate Safety and Effectiveness of Multicompartmental Dosimetry Planning.
The purpose of this study is to assess the safety and effectiveness of treating a tumor using a different planning method called MCD for the FDA-Approved device, TheraSphere.
- Trial name
- ADVANCE-MCD (NCT07669727)
- Testing
- TheraSphere
- Volunteers
- 140 people
- Sponsor
- Boston Scientific Corporation
Hepatitis C Virus Infection
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed Dose Combination in the Treatment of Hepatitis C Virus (HCV) Infection in Pediatric Participants Undergoing Cancer Chemotherapy
The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of ledipasvir/sofosbuvir (LDV/SOF) in treating hepatitis C virus (HCV) infection in pediatric participants who are undergoing cancer…
- Trial name
- NCT02868242
- Testing
- LDV/SOF
- Where
- Egypt
- Volunteers
- 19 people
- Sponsor
- Gilead Sciences
Hepatocellular Carcinoma
A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)
The purpose of this study is to assess the efficacy and safety of tiragolumab, an anti-TIGIT monoclonal antibody, when administered in combination with atezolizumab and bevacizumab as first-line treatment, in participants with…
- Trial name
- SKYSCRAPER-14 (NCT05904886)
- Testing
- Atezolizumab, Bevacizumab, Tiragolumab
- Where
- 171 sites in United States, Belgium and 25 more
- Volunteers
- 687 people
- Sponsor
- Hoffmann-La Roche
Liver Metastases
AvidinOX + [177Lu]DOTA-biotin (or 177Lu-ST2210) Complex in Patients With Liver Metastases From Colorectal Cancer
The purpose of the study is to assess a new treatment for patients with liver tumor metastases from colorectal cancer. The treatment has never been used in humans before.
- Trial name
- NCT02053324
- Testing
- AvidinOX/ST2210
- Where
- 4 sites in Austria, Italy
- Volunteers
- 14 people
- Sponsor
- Alfasigma S.p.A.
Liver Neoplasms, Hepatocellular Carcinoma
The HistoSonics System for Treatment of Primary and Metastatic Liver Tumors Using Histotripsy
This trial is a single arm, non-randomized prospective trial. The objective of this trial is to evaluate the efficacy and safety of the HistoSonics System for the treatment of primary or metastatic tumors located in the liver.
- Conditions
- Liver Neoplasms, Hepatocellular Carcinoma, Liver Metastases
- Trial name
- #HOPE4LIVER US (NCT04572633)
- Testing
- HistoSonics System
- Where
- 7 sites in United States
- Volunteers
- 47 people
- Sponsor
- HistoSonics, Inc.
Colon Cancer Liver Metastasis
Phase 2 Study of Thermodox as Adjuvant Therapy With Thermal Ablation (RFA) in Treatment of Metastatic Colorectal Cancer(mCRC)
The purpose of this study is to determine the safety and efficacy of Thermodox, a thermally sensitive liposomal doxorubicin, in combination with thermal ablation in the treatment of hepatic colorectal liver metastases (CRLM).
- Trial name
- ABLATE (NCT01464593)
- Testing
- Lyso-Thermosensitive Liposomal Doxorubicin, 5% Dextrose Solution, ThermoDox
- Where
- 4 sites in United States
- Volunteers
- 2 people
- Sponsor
- Imunon
Hepatocellular Carcinoma
A Study of AK112 in Patients With Unresectable Hepatocellular Carcinoma (HCC)
Phase II open label, multicenter study to evaluate the efficacy and safety of AK112 (PD-1/VEGF Bispecific) in patients with unresectable hepatocellular carcinoma (HCC).
- Trial name
- NCT05432492
- Testing
- AK112
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Akeso
Melanoma, Non Small Cell Lung Cancer
Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors
AI-061 is a co-formulation drug product (DP) consisting of 1:1 ratio mix of AI-025, an anti-PD-1 antibody, and ONC-392, an anti-CTLA-4 antibody.
- Conditions
- Melanoma, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, High Grade Serous Adenocarcinoma of Ovary
- Trial name
- PRESERVE-009 (NCT05858736)
- Testing
- AI-061
- Where
- 5 sites in Australia
- Volunteers
- 18 people
- Sponsor
- OncoC4, Inc.
Hepatocellular Carcinoma Non-resectable, Metastatic Colorectal Cancer
Safety and Effectiveness of Eye90 Microspheres™ in the Treatment of Unresectable Hepatocellular Carcinoma (HCC) and Metastatic Colorectal Cancer (mCRC)
The purpose of this study is to evaluate the safety of treatment with Eye90 microspheres in patients with unresectable Hepatocellular Carcinoma (HCC) and metastatic Colorectal Cancer (mCRC).
- Conditions
- Hepatocellular Carcinoma Non-resectable, Metastatic Colorectal Cancer, Liver Cancer
- Trial name
- NCT04926376
- Testing
- Eye90 Microspheres
- Where
- New Zealand
- Volunteers
- 8 people
- Sponsor
- ABK Biomedical